MAP1LC3B and melanoma: Moreover, increased MAP1LC3B expression typically shows unfavorable outcomes in lung, melanoma, and pancreatic cancers [25,26], whereas the loss of MAP1LC3B has been reported in several solid tumors, including brain cancer [27], prostate cancer [28], and breast cancer, indicating that MAP1LC3B expression in cancer is still controversial.